Halozyme Therapeutics, Inc. announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. Dr. Krishnan currently serves as Group Vice President of Growth at DaVita, Inc. He was co-lead of the DaVita Venture Group, where he oversaw strategic partnerships in technology and research and development within the organization.

In his current role, he also oversees aspects of medical policy in Washington, D.C. Dr. Krishnan previously served as DaVita's Group Vice President of Research and Development and was the company's first international Chief Medical Officer. Prior to DaVita, he served in various roles at Amgen Inc., including as the Global Development Leader for Epogen® and Executive Director, Medical Policy for all of Amgen's domestic products. Prior to his time at Amgen, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group.

Dr. Krishnan earned his B.S. in pre-medicine from The Pennsylvania State University and M.D. from Jefferson Medical College at Thomas Jefferson University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in healthcare management from the Johns Hopkins Carey School of Business.